A PHASE I STUDY OF AZD9291 IN PATIENTS WITH EGFR-TKI-RESISTANT ADVANCED NSCLC - UPDATED PROGRESSION FREE SURVIVAL AND DURATION OF RESPONSE DATA

被引：2

作者：

Jaenne, P. A. ^{[1
]}

Ahn, M. -J. ^{[2
]}

Kim, D. -W. ^{[3
]}

Kim, S. -W. ^{[4
]}

Planchard, D. ^{[5
]}

Ramalingam, S. S. ^{[6
]}

Frewer, P. ^{[7
]}

Cantarini, M. ^{[8
]}

Ghiorghiu, S. ^{[9
]}

Yang, J. C. -H. ^{[10
]}

机构：

[1] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA 02115 USA

[2] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Internal Med,Hematol,Oncol, Seoul, South Korea

[3] Seoul Natl Univ Hosp, Dept Internal Med, Seoul 110744, South Korea

[4] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea

[5] Gustave Roussy, Dept Med Oncol & Translat Res, Thorac Unit, Villejuif, France

[6] Emory Univ, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA

[7] Astra Zeneca, ECD Biometr, Macclesfield, Cheshire, England

[8] Astra Zeneca, Global Med Dept, Oncol, Macclesfield, Cheshire, England

[9] Astra Zeneca, Global Med Dev, Luton, Herts, England

[10] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan

来源：

ANNALS OF ONCOLOGY | 2015年 / 26卷

关键词：

D O I：

10.1093/annonc/mdv128.5

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA3

引用

页数：1

共 50 条

[31] CNS response to osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFR-TKI sensitising mutation (EGFRm)-positive advanced non-small cell lung cancer (NSCLC): Data from the FLAURA study
Vansteenkiste, J.
Reungwetwattana, T.
Nakagawa, K.
Cho, B. C.
Cobo Dols, M. A.
Cho, E. K.
Bertolini, A.
Bohnet, S.
Zhou, C.
Lee, K. H.
Nogami, N.
Okamoto, I.
Leighl, N.
Hodge, R.
McKeown, A.
Brown, A. P.
Rukazenkov, Y.
Ramalingam, S.
ANNALS OF ONCOLOGY, 2017, 28 : 189 - 189
[32] Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study
Mok, T.
Camidge, D. R.
Gadgeel, S. M.
Rosell, R.
Dziadziuszko, R.
Kim, D-W
Perol, M.
Ou, S-H, I
Ahn, J. S.
Shaw, A. T.
Bordogna, W.
Smoljanovic, V
Hilton, M.
Ruf, T.
Noe, J.
Peters, S.
ANNALS OF ONCOLOGY, 2020, 31 (08) : 1056 - 1064
[33] Updated safety and efficacy results from phase I/II study of HM61713 in patients (pts) with EGFR mutation positive non-small cell lung cancer (NSCLC) who failed previous EGFR-tyrosine kinase inhibitor (TKI).
Park, Keunchil
Lee, Jong-Seok
Lee, Ki Hyeong
Kim, Joo-Hang
Min, Young Joo
Cho, Jae Yong
Han, Ji-Youn
Kim, Bong-Seog
Kim, Jin-Soo
Lee, Dae Ho
Kang, Jin Hyoung
Cho, Eun Kyung
Jang, In-Jin
Jung, Jina
Kim, Hyo-Yeon
Sin, Hui Jung
Son, Jeewoong
Woo, Jong Soo
Kim, Dong-Wan
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[34] Final Progression-free survival interim overall survival, and biomarker analyses of CHOICE-01: A Phase III study of toripalimab versus placebo in combination with first-line chemotherapy for advanced NSCLC without EGFR/ALK mutations
Wang, Jie
Wang, Zhijie
Wu, Lin
Li, Baolan
Cheng, Ying
Li, Xiaoling
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (36)
[35] The progression-free survival of the first-line EGFR-TKI is a strong prognosticator of the second-line osimertinib in non-small cell lung cancer (NSCLC) patients with EGFR-T790M mutation: A real-world study
Tang, X.
Qian, W-L.
Pang, T.
Gong, Y-L.
Yang, Z-G.
ANNALS OF ONCOLOGY, 2021, 32 : S972 - S972
[36] Final Progression-Free Survival (PFS), Updated Overall Survival (OS), And Safety Data from the Global, Randomized, Phase 3 Alex Study of Alectinib (ALC) Versus Crizotinib (CRZ) in Untreated Advanced ALK plus Non-Small Cell Lung Cancer (NSCLC)
Hoffknecht, Petra
Mok, Tony
Shaw, Alice I.
Camidge, D. Ross
Gadgeel, Shirish
Rosell, Rafael
Dziadziuszko, Rafal
Kim, Dong-Wan
Perol, Maurice
Ou, Sai-Hong
Bordogna, Walter
Smoljanovic, Vlatka
Hilton, Magalie
Peters, Solange
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 236 - 236
[37] Updated efficacy and safety data from the phase I/II ARROW study of pralsetinib in patients (pts) with advanced RET fusion plus non-small cell lung cancer (NSCLC)
Besse, B.
Griesinger, F.
Curigliano, G.
Thomas, M.
Subbiah, V.
Baik, C. S.
Tan, D. S. W.
Lee, D. H.
Garralda, E.
Kim, D-W.
Van Der Wekken, A. J.
Gainor, J.
Paz-Ares, L.
Liu, S. V.
Bowles, D. W.
Zalutskaya, A.
Ruf, T.
Rahman, A.
Chen, G.
Mazieres, J.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S1083 - S1084
[38] Overall survival (OS) from the AURA3 phase III study: Osimertinib vs platinum-pemetrexed (plt-pem) in patients (pts) with EGFR T790M advanced non-small cell lung cancer (NSCLC) and progression on a prior EGFR-tyrosine kinase inhibitor (TKI)
Wu, Y-L.
Mok, T. S. K.
Han, J-Y.
Ahn, M-J.
Delmonte, A.
Ramalingam, S. S.
Kim, S-W.
Shepherd, F. A.
Laskin, J.
He, Y.
Akamatsu, H.
Theelen, W. S. M. E.
Su, W-C.
John, T.
Sebastian, M.
Mann, H.
Miranda, M.
Laus, G.
Rukazenkov, Y.
Papadimitrakopoulou, V.
ANNALS OF ONCOLOGY, 2019, 30
[39] Final progression-free survival, interim overall survival, and biomarker analyses of CHOICE-01: A phase 3 study of toripalimab versus placebo in combination with first-line chemotherapy for advanced NSCLC without EGFR/ALK mutations.
Wang, Jie
Wang, Zhijie
Wu, Lin
Li, Baolan
Cheng, Ying
Li, Xiaoling
Wang, Xicheng
Han, Liang
Wu, Xiaohong
Fan, Yun
Yu, Yan
Lv, Dongqing
Shi, Jianhua
Huang, Jianjin
Zhou, Shaozhang
Han, Baohui
Sun, Guogui
Guo, Qisen
Ji, Youxin
Zhu, Xiaoli
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[40] A phase IV study using multi-omits to identify mechanisms of response and resistance to crizotinib in ALK plus advanced non-small cell lung cancer (NSCLC) patients with distinct progression free survival outcomes.
du Tertre, Mathilde Couetoux
Tremblay, Lise
Bouchard, Nicole
Diaconescu, Razvan
Blais, Normand
Camlioglu, Errol
Constantin, Andre
Hoffert, Cyrla
Gambaro, Karen
Srivastava, Archana
Greenwood, Celia
Couture, Christian
McNamara, Suzan
Batist, Gerald
Cohen, Victor
Agulnik, Jason Scott
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35

← 1 2 3 4 5 →